Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
2020 · New England Journal of Medicine · 6,783 citations
https://doi.org/10.1056/nejmoa1915745
Y
Yulei Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
157
Papers
27.7K
Citations
46
h-index
75
i10-index
Yulei Wang is an academic researcher from Nanjing Agricultural University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Cancer-related molecular mechanisms research & Ferroptosis and cancer prognosis. The author has an h-index of 46, co-authored 134 publications.
ORCID: 0000-0002-9057-9786Papers by this author
worksTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
2018 · Nature · 5,347 citations
https://doi.org/10.1038/nature25501
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
2012 · Nature · 1,103 citations
https://doi.org/10.1038/nature11249
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
2023 · The Lancet · 415 citations
https://doi.org/10.1016/s0140-6736(23)01796-8
Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays
2006 · BMC Genomics · 302 citations
https://doi.org/10.1186/1471-2164-7-59
Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter
2016 · Oncogene · 84 citations
https://doi.org/10.1038/onc.2016.170
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat